Holen Sie sich die Stockscreener-App
33.17
8.96%
-3.31
Schlusskurs vom Vortag:
$36.48
Offen:
$36.8
24-Stunden-Volumen:
264.08K
Relative Volume:
0.35
Marktkapitalisierung:
$1.89B
Einnahmen:
$205.63M
Nettoeinkommen (Verlust:
$40.57M
KGV:
50.27
EPS:
0.6599
Netto-Cashflow:
$52.37M
1W Leistung:
-6.40%
1M Leistung:
+4.07%
6M Leistung:
+41.56%
1J Leistung:
+309.49%
1-Tages-Spanne:
$33.10
$37.49
1-Wochen-Bereich:
$33.18
$40.22
52-Wochen-Spanne:
$5.35
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
33.10 | 2.08B | 205.63M | 40.57M | 52.37M | 0.6599 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.84 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.46 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.22 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-05 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Aug Weekly: Can Stoke Therapeutics Inc grow without external fundingMarket Growth Review & Stock Market Timing Techniques - baoquankhu1.vn
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 33,243 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $174,200.00 in Stock - MarketBeat
Insider Sell: Adrian Krainer Sells 33,243 Shares of Stoke Therap - GuruFocus
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Highs Report: Is Stoke Therapeutics Inc in a long term uptrendPortfolio Risk Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Cresset Asset Management LLC Invests $771,000 in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD By Investing.com - Investing.com Canada
Stoke Therapeutics (NASDAQ:STOK) Hits New 52-Week HighStill a Buy? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD - Investing.com South Africa
Stoke Therapeutics earnings in focus amid Dravet trial progress - Investing.com South Africa
Stoke Therapeutics (NASDAQ:STOK) Shares Up 6%Still a Buy? - MarketBeat
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
A Look At Stoke Therapeutics (STOK) Valuation After NEJM Zorevunersen Dravet Syndrome Data Publication - simplywall.st
Stoke Therapeutics Hits New 52-Week High of $39.81, Up 146.41% - Markets Mojo
Stoke Therapeutics Hits Day Low at $33.50 Amid Price Pressure - Markets Mojo
Rhenman & Partners Asset Management AB Invests $5.88 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat
Biogen’s Dravet And SMA Advances Add Depth To Long Term Story - Sahm
Can Stoke Therapeutics Inc. stock deliver sustainable ROE2026 WrapUp & Smart Allocation Stock Reports - Naître et grandir
Vanguard Group Inc. Buys 217,616 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rate Cut: What are the analyst revisions for MESAIs Stoke Therapeutics Inc stock a good investment in YEARWeekly Stock Report & Stepwise Swing Trade Plans - baoquankhu1.vn
How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline - Yahoo Finance
Insider Sell: Adrian Krainer Sells 7,229 Shares of Stoke Therape - GuruFocus
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - The AI Journal
Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative
Stoke Therapeutics (STOK) director sells 7,229 shares under 10b5-1 plan - Stock Titan
Is Stoke Therapeutics (STOK) Still Attractive After A 346% One Year Share Price Surge - simplywall.st
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith By Investing.com - Investing.com Australia
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith - Investing.com South Africa
Stoke Therapeutics Awards Discretionary Bonus to CEO Smith - TipRanks
Stoke Therapeutics (NASDAQ: STOK) awards CEO Ian F. Smith $697,125 2025 bonus equivalent - Stock Titan
STOK: Phase 3 Dravet study nears full enrollment, with strong efficacy and broad market potential - TradingView
Stoke Therapeutics stock hits 52-week high at 38.8 USD By Investing.com - Investing.com Nigeria
STOK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[144] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Sets New 1-Year HighWhat's Next? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 38.8 USD - Investing.com India
Portfolio Shifts: What dividend growth rate does Stoke Therapeutics Inc offerJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
(STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily
STOK PE Ratio & Valuation, Is STOK Overvalued - Intellectia AI
Stoke Therapeutics (STOK) Investor Outlook: A Promising Biotech with 17.3% Upside Potential - DirectorsTalk Interviews
Stoke Therapeutics Opens with 6.45% Gain, Outperforming S&P 500's 0.69% - Markets Mojo
Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Risk Analysis: What is the earnings history of Stoke Therapeutics IncJuly 2025 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PharmiWeb.com
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK) - TechStock²
Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus
Wolfe Research Initiates Coverage of Stoke Therapeutics (STOK) with Outperform Recommendation - Nasdaq
Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics - Benzinga
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):